Adam Craig Sells 47,436 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Chairman Adam Craig sold 47,436 shares of X4 Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the sale, the chairman directly owned 328,651 shares of the company’s stock, valued at approximately $1,459,210.44. This trade represents a 12.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

X4 Pharmaceuticals Price Performance

XFOR opened at $4.22 on Friday. The company has a current ratio of 11.30, a quick ratio of 9.98 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $418.40 million, a P/E ratio of -3.52 and a beta of 0.37. The stock has a 50-day moving average price of $4.05 and a 200-day moving average price of $3.96. X4 Pharmaceuticals, Inc. has a 12-month low of $2.45 and a 12-month high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The company had revenue of $8.81 million for the quarter, compared to analysts’ expectations of $2.42 million. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. Equities analysts predict that X4 Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On X4 Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Pettinga Financial Advisors LLC bought a new stake in X4 Pharmaceuticals in the second quarter valued at approximately $47,000. Indivisible Partners purchased a new stake in shares of X4 Pharmaceuticals during the fourth quarter valued at approximately $40,000. SummitTX Capital L.P. bought a new position in shares of X4 Pharmaceuticals in the first quarter worth approximately $46,000. Squarepoint Ops LLC bought a new position in shares of X4 Pharmaceuticals in the fourth quarter worth approximately $50,000. Finally, Two Sigma Investments LP purchased a new position in shares of X4 Pharmaceuticals in the third quarter worth $47,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on XFOR. Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 price target on the stock. Leerink Partners assumed coverage on shares of X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 target price on the stock. Finally, Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.25.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.